Baseline characteristics of older adults with AML on CALGB 361101 (Alliance) (n = 96)
| Baseline characteristics . | Median (range) or frequency (%) . |
|---|---|
| Demographics | |
| Age (years) median (range) | 72.7 (60.6-92.4) |
| % 60-64 | 14.6 |
| % 65-69 | 19.8 |
| % 70-74 | 24.0 |
| % 75-79 | 20.8 |
| % ≥80 | 20.8 |
| % female | 30.2 |
| % white | 90.6 |
| % non-Hispanic | 91.7 |
| % ECOG performance status ≤1 | 73.9 |
| Clinical onset of AML | |
| % De novo | 63.2 |
| % Therapy-related | 11.6 |
| % MDS/AHD | 25.2 |
| ELN classification | |
| % Normal | 27.4 |
| % Intermediate-II | 22.1 |
| % Adverse | 38.9 |
| % No diagnosis cytogenetics | 11.6 |
| Baseline characteristics . | Median (range) or frequency (%) . |
|---|---|
| Demographics | |
| Age (years) median (range) | 72.7 (60.6-92.4) |
| % 60-64 | 14.6 |
| % 65-69 | 19.8 |
| % 70-74 | 24.0 |
| % 75-79 | 20.8 |
| % ≥80 | 20.8 |
| % female | 30.2 |
| % white | 90.6 |
| % non-Hispanic | 91.7 |
| % ECOG performance status ≤1 | 73.9 |
| Clinical onset of AML | |
| % De novo | 63.2 |
| % Therapy-related | 11.6 |
| % MDS/AHD | 25.2 |
| ELN classification | |
| % Normal | 27.4 |
| % Intermediate-II | 22.1 |
| % Adverse | 38.9 |
| % No diagnosis cytogenetics | 11.6 |
AHD, antecedent hematologic disorder; AML, acute myeloid leukemia; ELN, European LeukemiaNet; MDS, myelodysplastic syndromes.